Publication:
Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: Results from the TREAT Asia HIV Observational Database

dc.contributor.authorS. H. Hanen_US
dc.contributor.authorJ. Zhouen_US
dc.contributor.authorM. P. Leeen_US
dc.contributor.authorH. Zhaoen_US
dc.contributor.authorY. M.A. Chenen_US
dc.contributor.authorN. Kumarasamyen_US
dc.contributor.authorS. Pujarien_US
dc.contributor.authorC. Leeen_US
dc.contributor.authorS. F.S. Omaren_US
dc.contributor.authorR. Ditangcoen_US
dc.contributor.authorN. Phanuphaken_US
dc.contributor.authorS. Kiertiburanakulen_US
dc.contributor.authorR. Chaiwarithen_US
dc.contributor.authorT. P. Meratien_US
dc.contributor.authorE. Yunihastutien_US
dc.contributor.authorJ. Tanumaen_US
dc.contributor.authorV. Saphonnen_US
dc.contributor.authorA. H. Sohnen_US
dc.contributor.authorJ. Y. Choien_US
dc.contributor.authorC. V. Meanen_US
dc.contributor.authorV. Saphonnen_US
dc.contributor.authorK. Vohithen_US
dc.contributor.authorF. J. Zhangen_US
dc.contributor.authorH. X. Zhaoen_US
dc.contributor.authorN. Hanen_US
dc.contributor.authorP. C.K. Lien_US
dc.contributor.authorM. P. Leeen_US
dc.contributor.authorN. Kumarasamyen_US
dc.contributor.authorS. Saghayamen_US
dc.contributor.authorC. Ezhilarasien_US
dc.contributor.authorS. Pujarien_US
dc.contributor.authorK. Joshien_US
dc.contributor.authorA. Makaneen_US
dc.contributor.authorD. N. Wirawanen_US
dc.contributor.authorF. Yulianaen_US
dc.contributor.authorE. Yunihastutien_US
dc.contributor.authorD. Imranen_US
dc.contributor.authorA. Widhanien_US
dc.contributor.authorS. Okaen_US
dc.contributor.authorJ. Tanumaen_US
dc.contributor.authorT. Nishijimaen_US
dc.contributor.authorJ. Y. Choien_US
dc.contributor.authorS. H. Hanen_US
dc.contributor.authorJ. M. Kimen_US
dc.contributor.authorC. K.C. Leeen_US
dc.contributor.authorB. L.H. Simen_US
dc.contributor.authorR. Daviden_US
dc.contributor.authorA. Kamarulzamanen_US
dc.contributor.authorA. Kajindranen_US
dc.contributor.authorR. Ditangcoen_US
dc.contributor.authorE. Uyen_US
dc.contributor.authorR. Bantiqueen_US
dc.contributor.authorY. M.A. Chenen_US
dc.contributor.authorW. W. Wongen_US
dc.contributor.authorL. H. Kuoen_US
dc.contributor.authorO. T. Ngen_US
dc.contributor.authorA. Chuaen_US
dc.contributor.authorL. S. Leeen_US
dc.contributor.authorA. Lohen_US
dc.contributor.authorP. Phanuphaken_US
dc.contributor.authorK. Ruxrungthamen_US
dc.contributor.authorM. Khongphattanayothinen_US
dc.contributor.authorS. Sungkanuparphen_US
dc.contributor.authorN. Sanmeemaen_US
dc.contributor.authorT. Sirisanthanaen_US
dc.contributor.authorR. Chaiwarithen_US
dc.contributor.authorW. Kotarathititumen_US
dc.contributor.authorV. K. Nguyenen_US
dc.contributor.authorV. H. Buien_US
dc.contributor.authorT. T. Caoen_US
dc.contributor.authorT. T. Phamen_US
dc.contributor.authorD. D. Cuongen_US
dc.contributor.authorH. L. Haen_US
dc.contributor.authorA. H. Sohnen_US
dc.contributor.authorN. Durieren_US
dc.contributor.authorD. A. Cooperen_US
dc.contributor.authorB. Petersenen_US
dc.contributor.authorJ. Zhouen_US
dc.contributor.authorA. Jiamsakulen_US
dc.contributor.otherYonsei University College of Medicineen_US
dc.contributor.otherUniversity of New South Wales (UNSW) Australiaen_US
dc.contributor.otherQueen Elizabeth Hospital Hong Kongen_US
dc.contributor.otherBeijing Ditan Hospitalen_US
dc.contributor.otherNational Yang-Ming University Taiwanen_US
dc.contributor.otherYR Gaitonde Centre for AIDS Research and Educationen_US
dc.contributor.otherInstitute of Infectious Diseasesen_US
dc.contributor.otherHospital Sungai Bulohen_US
dc.contributor.otherUniversity of Malaya Medical Centreen_US
dc.contributor.otherGokilaen_US
dc.contributor.otherThe HIV Netherlands Australia Thailand Research Collaborationen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherResearch Institute for Health Sciencesen_US
dc.contributor.otherUniversitas Udayanaen_US
dc.contributor.otherUniversity of Indonesia, RSUPN Dr. Cipto Mangunkusumoen_US
dc.contributor.otherNational Center for Global Health and Medicineen_US
dc.contributor.otherNational Center for HIV/AIDSen_US
dc.contributor.otherFoundation for AIDS Researchen_US
dc.contributor.otherTan Tock Seng Hospitalen_US
dc.contributor.otherNational Hospital for Tropical Diseasesen_US
dc.contributor.otherBach Mai Hospitalen_US
dc.contributor.otheramfAR - The Foundation for AIDS Researchen_US
dc.date.accessioned2018-11-09T02:41:16Z
dc.date.available2018-11-09T02:41:16Z
dc.date.issued2014-02-01en_US
dc.description.abstractObjectives: We evaluated the effect of the time interval between the initiation of antiretroviral therapy (ART) and the initiation of tuberculosis (TB) treatment on clinical outcomes in HIV/TB-coinfected patients in an Asian regional cohort. Methods: Adult HIV/TB-coinfected patients in an observational HIV-infected cohort database who had a known date of ART initiation and a history of TB treatment were eligible for study inclusion. The time interval between the initiation of ART and the initiation of TB treatment was categorized as follows: TB diagnosed while on ART, ART initiated ≤90 days after initiation of TB treatment ('early ART'), ART initiated >90 days after initiation of TB treatment ('delayed ART'), and ART not started. Outcomes were assessed using survival analyses. Results: A total of 768 HIV/TB-coinfected patients were included in this study. The median CD4 T-cell count at TB diagnosis was 100 [interquartile range (IQR) 40-208] cells/μL. Treatment outcomes were not significantly different between the groups with early ART and delayed ART initiation. Kaplan-Meier analysis indicated that mortality was highest for those diagnosed with TB while on ART (3.77 deaths per 100 person-years), and the prognoses of other groups were not different (in deaths per 100 person-years: 2.12 for early ART, 1.46 for delayed ART, and 2.94 for ART not started). In a multivariate model, the interval between ART initiation and TB therapy initiation did not significantly impact all-cause mortality. Conclusions: A negative impact of delayed ART in patients coinfected with TB was not observed in this observational cohort of moderately to severely immunosuppressed patients. The broader impact of earlier ART initiation in actual clinical practice should be monitored more closely. © 2013 British HIV Association.en_US
dc.identifier.citationHIV Medicine. Vol.15, No.2 (2014), 77-85en_US
dc.identifier.doi10.1111/hiv.12073en_US
dc.identifier.issn14681293en_US
dc.identifier.issn14642662en_US
dc.identifier.other2-s2.0-84891828094en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/34311
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84891828094&origin=inwarden_US
dc.subjectMedicineen_US
dc.titlePrognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: Results from the TREAT Asia HIV Observational Databaseen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84891828094&origin=inwarden_US

Files

Collections